IRLAB Therapeutics - Screening platform continues to bear fruit

13.05.22 10:42
Edison Investment Research

IRLAB Therapeutics’ Q122 report recapped many of the research and development highlights shared on the company’s inaugural capital markets day in March, including Phase IIb/III clinical trial for lead asset mesdopetam, for the treatment of levodopa induced dyskinesias (LIDS) in Parkinson’s disease (PD) through a partnership with Ipsen and Phase IIb clinical trials for pirepemat in the prevention of falls in PD. Management continues to demonstrate the value of its Innovative Screening Platform (ISP). In the quarter, IRL757 was nominated as a new preclinical candidate that IRLAB will investigate as a potential treatment for apathy. IRL757 joins IRL942 (a potential cognitive function modulator) in the preclinical pipeline. Both are expected to begin Phase I trials in 2023. We are reviewing our forecasts.

hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
3,75 € 3,57 € 0,18 € +5,04% 24.05./07:30
ISIN WKN Jahreshoch Jahrestief
SE0012675361 A2PLBE 7,50 € 2,74 €
Handelsplatz Letzter Veränderung  Zeit
Berlin 3,75 € +5,04%  23.05.22
Frankfurt 3,505 € +0,14%  23.05.22
  = Realtime
Aktien des Tages

Jetzt für den kostenfreien Newsletter "Aktien des Tages" anmelden und keinen Artikel unseres exklusiven Labels AC Research mehr verpassen.

Das Abonnement kann jederzeit wieder beendet werden.

Meistgelesene Artikel
Aktuelle Diskussionen
Antw. Thema Zeit
  Löschung 25.04.21
RSS Feeds

Bitte warten...